

## Melovem

### Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification <sup>1</sup> issued on	Commission Decision Issued <sup>2</sup> / amended on	Product Information affected <sup>3</sup>	Summary
R/0008	Renewal of the marketing authorisation.	10/04/2014	06/06/2014	SPC, Annex II, Labelling and PL	The European Commission renewed the marketing authorisation for the product.
IB/0007	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	03/01/2014	06/02/2014	SPC, Labelling and PL	The Agency accepted the variation to harmonise the SPC and PL of the generic product with the reference product.
IA/0006	B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	18/12/2013	n/a		The Agency accepted the variation to submit an updated Ph. Eur. certificate of suitability from an already approved manufacturer.
IAIN/0005/G	This was an application for a group of variations.  B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer	18/12/2013	n/a		The Agency accepted a grouped variation concerning submission of a Ph. Eur. certificate of suitability from an already approved manufacturer and from a new manufacturer.

<sup>1</sup> Notifications are issued for type I variations (unless part of a group including a type II variation or higher procedure or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A CD is issued for procedures that affect the terms of the marketing authorisation (e.g. SPC, Annex II, Labelling, PL). The CD is issued within 2 months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within 1 year for other procedures.

<sup>3</sup> SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)				
X/0004	Annex I_2.(c) Change or addition of a new strength/potency	18/07/2013	25/09/2013	SPC, Annex II, Labelling and PL	The European Commission amended the decision granting the marketing authorisation to add a new strength 30 mg/ml solution for injection for cattle and pigs.
X/0003	Annex I_2.(c) Change or addition of a new strength/potency	18/07/2013	25/09/2013	SPC, Annex II, Labelling and PL	The European Commission amended the decision granting the marketing authorisation to add a new strength 20 mg/ml solution for injection for cattle, pigs and a new target species horses.
IB/0001	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH	08/04/2010	03/11/2010	SPC, Labelling and PL	The Agency approved a variation to update the SPC in line with the reference product for the indication in pigs.
IAIN/0002/G	This was an application for a group of variations.  C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system	09/07/2010	09/07/2010		The Agency approved a grouped variation concerning a change in the back-up to the QPPV and change in DDPS.